The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis
MH Umbehr, M Muentener, T Hany, T Sulser… - European urology, 2013 - Elsevier
CONTEXT: The role of positron emission tomography (PET) and PET/computed tomography
(PET/CT) in prostate cancer (PCa) imaging is still debated, although guidelines for their use …
(PET/CT) in prostate cancer (PCa) imaging is still debated, although guidelines for their use …
[HTML][HTML] PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status
S Lütje, S Heskamp, AS Cornelissen, TD Poeppel… - Theranostics, 2015 - ncbi.nlm.nih.gov
Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to
substantial morbidity and mortality. At present, imaging of PCa has become increasingly …
substantial morbidity and mortality. At present, imaging of PCa has become increasingly …
Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are …
JJ Morigi, PD Stricker, PJ van Leeuwen… - Journal of nuclear …, 2015 - Soc Nuclear Med
In prostate cancer with biochemical failure after therapy, current imaging techniques have a
low detection rate at the prostate-specific antigen (PSA) levels at which targeted salvage …
low detection rate at the prostate-specific antigen (PSA) levels at which targeted salvage …
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
SP Rowe, KJ Macura, E Mena, AL Blackford… - Molecular imaging and …, 2016 - Springer
Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate …
Y Chen, M Pullambhatla, CA Foss, Y Byun… - Clinical cancer …, 2011 - AACR
Purpose: We have synthesized and evaluated in vivo 2-(3-{1-carboxy-5-[(6-[18F] fluoro-
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid,[18F] DCFPyL, as a potential …
pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid,[18F] DCFPyL, as a potential …
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with …
SY Cho, KL Gage, RC Mease… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein
expressed on the surface of prostate cancer (PCa) cells, particularly in androgen …
expressed on the surface of prostate cancer (PCa) cells, particularly in androgen …
Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent …
Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
PET imaging in prostate cancer: focus on prostate-specific membrane antigen
Prostate cancer (PCa) is the second leading cause of cancer-related death in American
men. Positron emission tomography/computed tomography (PET/CT) with emerging …
men. Positron emission tomography/computed tomography (PET/CT) with emerging …
Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer
FE von Eyben, K Kairemo - Nuclear medicine communications, 2014 - journals.lww.com
The aim of the study was to evaluate the diagnostic accuracy and clinical aspects of 11 C-
choline and 18 F-choline PET/computed tomography (CT) in patients with prostate cancer. A …
choline and 18 F-choline PET/computed tomography (CT) in patients with prostate cancer. A …
Consensus on molecular imaging and theranostics in prostate cancer
S Fanti, S Minozzi, G Antoch, I Banks, A Briganti… - The lancet …, 2018 - thelancet.com
Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate
cancer pose issues for the development of guidelines for their appropriate use. To tackle this …
cancer pose issues for the development of guidelines for their appropriate use. To tackle this …